Oncology (Pediatrics)
Individualized/Modified Chemotherapy (Dose Adjustment or Delay)
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. (opens new window)
Source: N Engl J Med 1998;338(8):499-505.
Indexed: PubMed 9468466
DOI: 10.1056/NEJM199802193380803
https://www.ncbi.nlm.nih.gov/pubmed/9468466 (opens new window)
Childhood cancer and the Jehovah's Witness faith. (opens new window)
Source: Pediatrics 1977;60(6):916-21.
Indexed: PubMed 600607
https://www.ncbi.nlm.nih.gov/pubmed/600607 (opens new window)
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. (opens new window)
Source: J Clin Oncol 2004;22(24):4888-92.
Indexed: PubMed 15611504
DOI: 10.1200/JCO.2004.02.101
https://www.ncbi.nlm.nih.gov/pubmed/15611504 (opens new window)
Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group AAML1331 Trial. (opens new window)
Source: JAMA Oncol 2022;8(1):79-87.
Indexed: PubMed 34762093
DOI: 10.1001/jamaoncol.2021.5206
https://pubmed.ncbi.nlm.nih.gov/34762093/ (opens new window)
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. (opens new window)
Source: Hematol Oncol 2014;32(1):40-6.
Indexed: PubMed 23963734
DOI: 10.1002/hon.2076
https://www.ncbi.nlm.nih.gov/pubmed/23963734 (opens new window)
Acute leukemia in Jehovah's Witnesses: a challenge for hematologists. (opens new window)
Source: Haematologica 2000;85(11):1221-2.
Indexed: PubMed 11064477
https://www.ncbi.nlm.nih.gov/pubmed/11064477 (opens new window)
Autologous and allogeneic stem cell transplant in Jehovah's Witnesses: a single-center experience on 22 patients. (opens new window)
Source: Bone Marrow Transplant 2016;51(7):1002-3.
Indexed: PubMed 26950381
DOI: 10.1038/bmt.2016.29
https://www.ncbi.nlm.nih.gov/pubmed/26950381 (opens new window)
Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. (opens new window)
Source: Bone Marrow Transplant 2003;32(4):433-6.
Indexed: PubMed 12900781
DOI: 10.1038/sj.bmt.1704179
https://www.ncbi.nlm.nih.gov/pubmed/12900781 (opens new window)
Bloodless (transfusion-free) hematopoietic stem cell transplants: the Mexican experience. (opens new window)
Source: Bone Marrow Transplant 2005;36(8):715-20.
Indexed: PubMed 16113672
DOI: 10.1038/sj.bmt.1705126
https://www.ncbi.nlm.nih.gov/pubmed/16113672 (opens new window)
Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. (opens new window)
Source: Br J Haematol 2004;127(3):264-79.
Indexed: PubMed 15491285
DOI: 10.1111/j.1365-2141.2004.05167.x
https://www.ncbi.nlm.nih.gov/pubmed/15491285 (opens new window)
Tratamiento de la leucemia aguda linfoblástica con poliquimioterapia sin hemoderivados en niños Testigos de Jehová. [Treatment of acute lymphoblastic leukemia using combination chemotherapy without blood-derived products in Jehovah's Witness children. (opens new window)
Source: Rev Med Hosp Gen Mex 2009;72(1):16-9.
Indexed: ISSN 0185-1063
https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=21009 (opens new window)